A Health Canada-approved clinical trial has demonstrated the ability of our medical therapy to successfully treat hundreds of thousands of Canadians who have become functionally or legally blind from the effects of the dry version of Age-Related Macular Degeneration (AMD). Treatment can potentially extend by years the sight of those whose vision is suffering through AMD’s early stages.
Treatment is non-invasive. It requires no drugs. Its use of our patented microcurrent technology, in a waveform specifically designed to treat the delicate structures of the retina, is potentially game-changing for hundreds of thousands of Canadians who suffer with AMD.